Allergy Therapeutics (LSE:AGY) ROCE % : -50.98% (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Allergy Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Allergy Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2023 was -50.98%.

Allergy Therapeutics ROCE % Historical Data

The historical data trend for Allergy Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics ROCE % Chart

Allergy Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROCE %

Get a 7-Day Free Trial

10.21

14.34

6.02

-19.22

-76.29

Allergy Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															20.57	-59.75	-28.51	-122.70	-50.98

Allergy Therapeutics ROCE % Calculation

Allergy Therapeutics's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	-39.325	/	( ( (72.948 - 18.053)	+	(66.769 - 18.565) )	/ 2 )
	=	-39.325	/	( (54.895	+	48.204)	/ 2 )
	=	-39.325	/	51.5495
	=	-76.29 %

Allergy Therapeutics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-23.454	/	( ( (66.769 - 18.565)	+	(69.077 - 25.272) )	/ 2 )
	=	-23.454	/	( ( 48.204	+	43.805 )	/ 2 )
	=	-23.454	/	46.0045
	=	-50.98 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Allergy Therapeutics (LSE:AGY) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Allergy Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Allergy Therapeutics (LSE:AGY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Allergy Therapeutics PLC (LSE:AGY) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

HHU:Germany

Address

Dominion Way, Worthing, West Sussex, GBR, BN14 8SA

Website

https://www.allergytherapeutics.com

Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergies with aluminum-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics (LSE:AGY) Headlines

No Headlines